Skip to main content

Published locations for CD123 may be a marker for residual disease and response evaluation in AML and B-ALL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. CD123 may be a marker for residual disease and response evaluation in AML and B-ALL

User login

  • Reset your password
  • /content/cd123-may-be-marker-residual-disease-and-response-evaluation-aml-and-b-all
  • /hematologynews/article/222302/aml/cd123-may-be-marker-residual-disease-and-response-evaluation-aml
  • /oncologypractice/article/222302/aml/cd123-may-be-marker-residual-disease-and-response-evaluation-aml
  • /hematology-oncology/article/222302/aml/cd123-may-be-marker-residual-disease-and-response-evaluation